返回ChemicalBook首页>CAS数据库列表>1826843-81-5

1826843-81-5

中文名称 Trastuzumab Deruxtecan
英文名称 Trastuzumab Deruxtecan
CAS 1826843-81-5
更新日期 2024/04/29 22:52:17
1826843-81-5 结构式 1826843-81-5 结构式

基本信息

中文别名
德卢替康-曲妥珠单抗
英文别名
Trastuzumab Deruxtecan

物理化学性质

储存条件Solution, -20°C, 2 years
溶解度溶于乙腈
Trastuzumab Deruxtecan价格(试剂级)
报价日期产品编号产品名称CAS号包装价格
2024/04/30HY-138298Trastuzumab Deruxtecan
Trastuzumab deruxtecan
1826843-81-51mg(10mg/mL * 100μL in Aqueous solution)6400元
2024/04/30HY-138298ATrastuzumab Deruxtecan
Trastuzumab deruxtecan
1826843-81-51 mg6400元
2023/10/26HY-138298Trastuzumab Deruxtecan
Trastuzumab deruxtecan
1826843-81-55mg(10mg/mL * 500μL in Aqueous solution)20000元

常见问题列表

生物活性
Trastuzumab deruxtecan (DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。 Trastuzumab deruxtecan 由人源化抗 HER2 抗体,酶促裂解的肽接头和拓扑异构酶 I 抑制剂组成。Trastuzumab deruxtecan 可用于 HER2 阳性乳腺癌和胃癌的研究。
体外研究

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC 50 of 109.7 pM.
Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells.

Cell Viability Assay

Cell Line: KPL‐4 and MDA‐MB‐468 cells
Concentration: 1, 10, 100, 1000, 10000 pM
Incubation Time: 5 days
Result: Killed both HER2‐positive KPL‐4 cells and HER2‐negative MDA‐MB‐468 cells.
体内研究

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition.
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model.

Animal Model: Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells
Dosage: 3 mg/kg
Administration: A single i.v.
Result: Almost all of the HER2‐positive and HER‐negative cells disappeared and there were little or no cancer cells remaining in the tumors.
"1826843-81-5" 相关产品信息